Epigene Labs
Epigene Labs is a Paris-based AI-native precision oncology data company that integrates fragmented multi-omic datasets into comprehensive disease atlases from 2 million curated cancer profiles, serving large biopharma and academic researchers.
- Company typePrivate
- Founded2019
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Epigene Labs firmographics
Firmographics- Name
- Epigene Labs
- Legal name
- SAS EPIGENE LABS
- Website
- https://epigenelabs.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Epigene Labs is a Paris-based AI-native precision oncology data company that integrates fragmented multi-omic datasets into comprehensive disease atlases from 2 million curated cancer profiles, serving large biopharma and academic researchers.
- Ownership category
- akta.pro rank
Epigene Labs industry classification
Industry- Product category
- Precision Oncology Bioinformatics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Epigenomics & Chromatin Profiling Services (HLAGANAF), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)
Keywords
Where Epigene Labs is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Epigene Labs business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- mCUBE Platform Licensing: Access to the mCUBE platform providing disease atlases, biomarker discovery, target identification, and patient selection capabilities, licensed to biopharma organizations through multi-year enterprise agreements. The company also plans to launch off-the-shelf curated dataset products for smaller biotechs and academic groups.
- Curated Data Products: Off-the-shelf curated omic datasets for smaller biotechs and academic research groups, continuously refreshed as new public data becomes available. This represents a new revenue stream enabled by the expansion to 2 million curated cancer profiles.
- Private Data Marketplaces: Custom private data marketplaces for biopharma partners integrating public omic data, commercial datasets, internal clinical trial data, and consortium data through secure multi-cloud architectures.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise platform access (mCUBE) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
Epigene Labs product offering
Product offeringCore offering
Epigene Labs develops and licenses the mCUBE platform, an AI-powered data curation and analytics system that integrates fragmented multi-omic datasets (genomics, transcriptomics, epigenomics) from public and commercial sources into comprehensive pan-cancer disease atlases. The platform is sold to biopharma clients via multi-year enterprise subscriptions and private data marketplace engagements to accelerate target discovery, biomarker identification, patient selection, and clinical trial optimization in precision oncology. The company also publishes the open-source InMoose and pyComBat Python toolkits for the bioinformatics community.
Product overview
Epigene Labs offers a unified product portfolio centered on the mCUBE platform, an AI-powered data intelligence platform for precision oncology. The mCUBE platform assembles fragmented multi-omic datasets into comprehensive disease atlases, supplemented by open-source bioinformatics tools including InMoose (Python implementation of R transcriptomics tools) and pyComBat (batch effects correction). The company also provides private data marketplace services for enterprise biopharma collaborations.
Differentiator
Problem solved
Functional benefit
Brands
- mCUBE: AI-powered platform that integrates fragmented multi-omic datasets into comprehensive disease atlases for precision oncology research and drug development.
- InMoose
Products and services
- mCUBE Platform AI-powered data platform that integrates fragmented multi-omic datasets (genomics, transcriptomics, epigenomics) from multiple public and commercial databases into comprehensive disease atlases, supporting target discovery, biomarker identification, patient selection, and clinical trial optimization for biopharma organizations.
- Disease Atlases Comprehensive, harmonized pan-cancer datasets built on top of curated omic data collections, unifying data across cohorts, institutions, and technologies to reconstruct broad and deep views of disease biology at scales up to ten times larger than current industry references such as TCGA. Used by biopharma R&D teams for cross-disease research and target validation.
- Private Data Marketplaces Custom data marketplaces tailored to individual biopharma partners, integrating public omic data, commercial datasets, internal clinical trial data, and consortium data through secure multi-cloud architectures and cloud-to-cloud data bridges. Used by enterprise biopharma for clinical development strategy and biomarker programs.
- InMoose (Integrated Multi-Omics Open Source Environment) Open-source Python framework for bulk transcriptomic data analysis that ports state-of-the-art R tools (ComBat, ComBat-Seq, limma, edgeR, DESeq2, splatter) into the Python ecosystem, featuring batch-effect correction, differential expression analysis, and data simulation. Distributed under GPL-3.0 license on GitHub and PyPI for global research use.
Quantifiable outcome
- R&D timelines reduced from months to days
- +9 more outcomes
Companies that use Epigene Labs
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Epigene Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature9 records
Epigene Labs partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, notable and supporting.
- ServiercoreMulti-year partnership launched in January 2022 to apply Epigene Labs' mCUBE platform to Servier's oncology clinical development programs. Expanded in March 2025 to accelerate and increase precision of Servier's oncology clinical trials. This is a flagship collaboration demonstrating the platform's enterprise value in a production clinical development setting.
- Institut CurienotablePartnership to improve ovarian cancer treatment through integration of Epigene Labs' multi-omic data platform with Institut Curie's cancer research expertise. Combines public omic data curation with Curie's clinical research capabilities.
- Certi-TrustsupportingCerti-Trust provides ISO 27001:2022 and HDS 2022 certification services for Epigene Labs' information security management and health data hosting practices.
- CloudflaresupportingCloudflare provides web hosting and security infrastructure for Epigene Labs' website (epigenelabs.com). Hosting location: 6 Place de la Madeleine, 75008 Paris, France.
- Harvard Innovation LabssupportingEpigene Labs was initially incubated at the Harvard Innovation Labs before launching operations in France. Provided early-stage support and resources.
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
Epigene Labs competitors and assessment
Company assessmentDirect peers
- Tempus AI: Tempus is a precision medicine data and AI platform that aggregates multi-modal clinical and molecular data to support oncology R&D and therapeutic development. Directly comparable as a data-driven precision oncology platform serving biopharma with curated datasets and analytics.
- Owkin: Owkin is a France-based AI precision medicine company that builds multimodal patient data networks and ML models for oncology drug discovery, with deep biopharma partnerships. Closely comparable as a European AI-oncology data platform serving biopharma.
- Flatiron Health: Flatiron Health (a Roche company) curates real-world oncology data from clinical and molecular sources and offers analytics for biopharma research. Comparable as an oncology-focused curated data and analytics provider for biopharma.
- SOPHiA Genetics: SOPHiA Genetics operates an AI genomics platform for multi-modal clinical genomics data analysis used by hospitals and biopharma. Comparable as a bioinformatics and multi-omic analytics platform with both clinical and research customers.
- Personalis: Personalis is a cancer genomics company offering tumor profiling assays and a clinical research platform for biopharma and academic customers. Comparable in using genomic data to support oncology drug development and biomarker discovery.
- DNAnexus: DNAnexus provides a cloud-based genomics and biomedical data platform used by biopharma and clinical researchers to manage, analyze, and share omic data. Comparable as a multi-omic data platform and bioinformatics environment serving biopharma R&D.
- Lifebit: Lifebit offers a federated genomics and biomedical data platform enabling researchers and biopharma to access and analyze large-scale omic datasets. Comparable as an enterprise genomics data and analytics platform for precision medicine.
- BC Platforms: BC Platforms provides a genomics data platform and analytics tooling used by biopharma and healthcare providers to operationalize genomic and clinical data. Comparable as a genomics data platform with biopharma customers.
Broad incumbents
- Foundation Medicine: Foundation Medicine (Roche) provides molecular profiling and genomic testing used to inform oncology research and treatment. Comparable at the level of large-scale molecular oncology data assets serving biopharma, though its core business is clinical diagnostic testing.
Emerging players
- Envisagenics: Envisagenics applies AI to RNA splicing data for therapeutic target discovery in oncology. Comparable at the AI-driven RNA/transcriptomic target discovery intersection; overlapping on AI-driven oncology target identification but focused on a narrower modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Epigene Labs social profiles
Digital presenceEpigene Labs compliance and trust
Trust signalCompliance2 records
Epigene Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Epigene Labs leadership team
Management profileNumber of profiles
Profiles16 records
Epigene Labs funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Epigene Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Epigene Labs
What does Epigene Labs do?
Epigene Labs develops and licenses the mCUBE platform, an AI-powered data curation and analytics system that integrates fragmented multi-omic datasets (genomics, transcriptomics, epigenomics) from public and commercial sources into comprehensive pan-cancer disease atlases. The platform is sold to biopharma clients via multi-year enterprise subscriptions and private data marketplace engagements to accelerate target discovery, biomarker identification, patient selection, and clinical trial optimization in precision oncology. The company also publishes the open-source InMoose and pyComBat Python toolkits for the bioinformatics community.
Is Epigene Labs a public or private company?
Epigene Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Epigene Labs founded?
Epigene Labs was founded in 2019. It employs 11 to 50 people.
Where is Epigene Labs based?
Epigene Labs is headquartered in Paris, France, in the Europe region.
How does Epigene Labs make money?
Three revenue lines are on record. mCUBE Platform Licensing is the primary driver. The others are curated Data Products and private Data Marketplaces.
Who are Epigene Labs's main competitors?
Direct peers on record are Tempus AI, Owkin, Flatiron Health, SOPHiA Genetics, Personalis, DNAnexus, Lifebit and BC Platforms. Foundation Medicine is listed as a broad incumbent. Envisagenics is listed as an emerging player.
Does Epigene Labs have an API?
No public API is recorded for Epigene Labs.
What industry is Epigene Labs in?
Epigene Labs's product category is Precision Oncology Bioinformatics Software. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 7372.